BPMC | Blueprint medicines corp - Stock Value & PE Ratio Analysis

3

24

15

Good Growth

AI analysis rates BPMC with a higher value score of 4.
It is mainly due to stable revenue growth, along with adequate safety shown in the balance sheet.
Over the past 3 months, BPMC has maintained a consecutive value rating of 4.0, slightly higher than the rating of 3.3 over the past 3 years, indicating higher growth opportunities for enterprise value.
Compared to all stocks in the Health Care sector, BPMC has a higher value rating.

BPMC Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/05/03 (Weekly Update)

BPMC Financial Forecast

Unit : USD

Update to 2025/5/4 (Quarterly Update)

BPMC Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	-0.74	59.3%	76.2%	149.41M	107.6%	-13.5%	-34.1%
2024Q2	-0.89	59.5%	-8.2%	128.18M	126.6%	-12.6%	-36.2%
2024Q1	-0.8	63.5%	-37.5%	138.16M	140%	33.4%	92.7%
2023Q4	-1.32	38.6%	-19.5%	96.12M	51.9%	19.5%	-154.1%
2023Q3	-1.82	31.3%	-10.8%	71.96M	85.5%	7.7%	-236.4%

Update to 2025/5/9 (Quarterly Update)

BPMC Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

BPMC Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of BPMC from 2015/04 till Now

2.53%
Cumulative Return: 0.25%
Annual Return: 33.15%
Volatility: 0.01
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from April, 2015 to May, 2025. (Total Trades: 1)